A Study of the Effectiveness and Safety of Nivolumab Plus Chemotherapy in Participants With Untreated Advanced/Recurrent Gastric Cancer
NCT05334719 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 500
Last updated 2025-06-27
Summary
The purpose of this study is to assess the effectiveness, safety, and actual treatment status of first-line nivolumab plus chemotherapy in participants with untreated advanced / recurrent gastric cancer in a Japanese real-world setting.
Conditions
- Stomach Neoplasms
Sponsors & Collaborators
-
Ono Pharmaceutical Co. Ltd
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-06-29
- Primary Completion
- 2026-01-16
- Completion
- 2026-09-30
Countries
- Japan
More Related Trials
-
Cisplatin and S-1 With or Without Nimotuzumab in Untreated Advanced Gastric Adenocarcinoma
NCT02370849 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
NCT02999295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer
NCT05913115 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by UFT in Serosa-positive Gastric Cancer (JCOG9206-2)
NCT00147147 ·Status: COMPLETED ·Phase: PHASE3
-
Clinical Study of Regorafenib and Nivolumab Plus Chemotherapy
NCT05394740 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
NCT03006705 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer
NCT01531452 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
NCT00209664 ·Status: SUSPENDED ·Phase: PHASE2
-
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
NCT02267343 ·Status: COMPLETED ·Phase: PHASE3
-
Postoperative Immunotherapy vs Standard Chemotherapy for Gastric Cancer With High Risk for Recurrence
NCT03443856 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Neoadjuvant Chemoradiation Plus Serplulimab in Patients With Locally Advanced Adenocarcinoma of Gastroesophageal Junction
NCT05918419 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer
NCT06054906 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer
NCT04503967 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer
NCT00519324 ·Status: COMPLETED ·Phase: PHASE2
-
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)
NCT03675737 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I/II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer
NCT00209638 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Neoadjuvant Nivolumab Plus SOX Versus Nivolumab Plus FLOT in Patients With HER2-negative Gastric and Gastroesophageal Junction Adenocarcinoma
NCT06440811 ·Status: COMPLETED
-
Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)
NCT03591731 ·Status: COMPLETED ·Phase: PHASE2
-
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
NCT01863745 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab, S-1 Combined With Oxaliplatin Versus Nivolumab as Neoadjuvant Therapy in Advanced Gastric Cancer
NCT04782791 ·Status: UNKNOWN ·Phase: PHASE2
-
Predicting the Efficacy in Advanced Gastric Cancer.
NCT06490055 ·Status: COMPLETED
-
Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer
NCT05535569 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Compare Different Response Evaluations to Neoadjuvant Chemotherapy for Gastric Cancer
NCT02179463 ·Status: UNKNOWN
-
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
NCT03382600 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients
NCT00960349 ·Status: COMPLETED ·Phase: PHASE1